Pharma channel feed

Ex-Mela chief Gul­fo joins the list of would-be FDA com­mish can­di­dates, col­or-cod­ed drug ap­proval plan in hand

9 years ago

Women are gain­ing more board seats in biotech, but re­al change is hap­pen­ing at a snail's pace

9 years ago
R&D

Banned from Twit­ter, Mar­tin Shkre­li whips up a new on­line tirade in re­sponse to a mock­ing dig from PhRMA chief

9 years ago

Fac­ing a deep­en­ing po­lit­i­cal cri­sis, PhRMA launch­es a ma­jor coun­ter­at­tack against its le­gion of crit­ics

9 years ago

Af­ter re­peat­ed set­backs on the check­point front, Bris­tol-My­ers scores a $625M pay­out from Mer­ck to set­tle patent fra­cas

9 years ago

The FDA’s cau­tion­ary Hall of Shame: 22 ‘break­through’ drugs that sud­den­ly crashed in PhI­II

9 years ago

Bris­tol-My­ers stag­gered by a stun­ning check­point set­back, hands Mer­ck a free pass on front­line lung can­cer com­bo

9 years ago
R&D

Syn­er­gy bags an FDA OK for con­sti­pa­tion ther­a­py Tru­lance in the lead up to an sN­DA

9 years ago

Ovid and Take­da cre­ate a one-team strat­e­gy to steer a neu­ro drug to the world

9 years ago

SEC hands Al­ler­gan a $15M speed­ing tick­et for blow­ing off dis­clo­sure rules in a tough 2014 fight against Valeant

9 years ago

Bio­gen to pay $1.25B to de-risk a Tec­fidera patent bat­tle, and For­ward Phar­ma’s shares rock­et up

9 years ago

In his lat­est broad­side on drug prices, Trump plays the Medicare ne­go­ti­a­tions card

9 years ago

Af­ter talk­ing to Trump about top FDA job, Bal­a­ji Srini­vasan erased his barbed crit­i­cism of the drug agency

9 years ago
People

Is Spin­raza worth $750K? Bio­gen says yes, spelling out re­duced death risk

9 years ago
R&D

Failed Ni­valis pares down to a skele­ton crew as it launch­es a sal­vage op­er­a­tion

9 years ago
R&D

As Trump fin­gers phar­ma on drug prices, ex­ecs step up with the lat­est vows of self dis­ci­pline

9 years ago

FDA re­jects Tesaro’s IV ver­sion of ro­lap­i­tant, cit­ing man­u­fac­tur­ing is­sues

9 years ago

Don­ald Trump promis­es to slash drug prices by bil­lions, pledg­ing ag­gres­sive fed­er­al bid­ding process

9 years ago

Dai­ichi Sankyo launch­es glob­al R&D re­struc­tur­ing, look­ing to slash costs in an over­haul

9 years ago
R&D

In a stun­ner, Mer­ck leaps ahead of ri­vals with com­bo Keytru­da/chemo at­tack on lung can­cer

9 years ago
R&D

Mer­ck KGaA splurges $230M on its pipeline, pay­ing Ver­tex for a slate of ear­ly-stage can­cer drugs

9 years ago

A hun­gry Take­da con­tin­ues deal spree with $125M T cell pact, op­tion to buy

9 years ago

Strug­gling Sarep­ta bounces back as an­a­lysts cheer the first trick­le of rev­enue for DMD drug

9 years ago
R&D

J&J In­no­va­tion ex­pands its biotech in­cu­ba­tor JLABS in­to Man­hat­tan

9 years ago
First page Previous page 337338339340341342343 Next page Last page
A service from the Financial Times